Intriguing Science: aging was modelled, and it’s not linear
A fascinating article, published in Cell on 25 July 2025, shows the results of Dr Ding and their team around aging. By analyzing proteomic profiles of several samples, they build a model of biological aging for several types of tissues. The analyses showed that aging is not a linear process, but accelerates around 50 years old, and blood vessels seem to be among the fastest to age. By developing accurate biological age markers per tissues, we pave the way to better tracking and care, targeting organs that are faster aging than other, and maybe on individual basis.
Here is the link to the article for more: DOI: 10.1016/j.cell.2025.06.047
European Medicine Agency (EMA)
The EMA’s Committee for Medicinal Products for Human Use (CHMP) held its monthly meeting from July 21 to 24, 2025. Here are the key takeaways:
- Aqneursa (levacetylleucine, Intrabio) received a recommendation for marketing authorization for the treatment of Niemann-Pick disease type C.
- Ekterly (sebetralstat, Kalvista Pharmaceuticals) received a positive opinion for the treatment of acute attacks of hereditary angioedema.
- Romvimza (vimseltinibm, Deciphera Pharmaceuticals/Ono Pharmaceuticals) was recommended for marketing authorization for the treatment of adults with symptomatic tenosynovial giant cell tumour.
- Tryngolza (olezarsen, Ionis Pharmaceuticals) received a positive opinion for the treatment of adults with familial chylomicronemia syndrome.
- Voranigo (vorasidenib, Servier) received a positive opinion for the treatment of low-grade astrocytoma or oligodendroglioma.
- Yeytuo (lenacapavir, Gilead Sciences) was recommended for marketing authorization as pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk.
- Zurzuvae (zuranolone, Biogen/ Supernus Pharmaceuticals) received a positive opinion for the treatment of postpartum depression in adults following childbirth.
- Kisunla (donanemab, Eli Lilly) received a recommendation for marketing authorization for the treatment of early Alzheimer’s disease, following a re-examination.
- The committee adopted positive opinions for four biosimilar medicines: Bildyos (denosumab, Henlius), for the treatment of osteoporosis and bone loss; Bilprevda (denosumab, Henlius), for the prevention of skeletal-related events in adults with advanced malignancies involving bone; Eyluxvi (aflibercept, Biolitec pharma), for the treatment of age-related macular degeneration and visual impairment; Usrenty (ustekinumab, Biosimilar Collaborations), for the treatment of Crohn’s disease, plaque psoriasis and paediatric plaque psoriasis, and psoriatic arthritis.
- Elevidys (delandistrogene moxeparvovec, Sarepta Therapeutics/ Roche) received a negative opinion for the treatment of Duchenne muscular dystrophy. In parallel, a 4th death was reported in the US raising the global safety concerns regarding gene therapies.
- Jelrix (cartilage-forming cells, autologous, TETEC Tissue Engineering Technologies) received a negative opinion from for the treatment of cartilage defects in the knee. CHMP meeting highlights.
US Food and Drug Administration (FDA)
- Anzupgo (delgocitinib, Leo Pharma) cream was approved for the topical treatment of moderate-to-severe chronic hand eczema in adults. Leo Pharma press release.
- Columvi (glofitamab-gxbm, Genentech) was rejected in combination with gemcitabine and oxaliplatin for the treatment of people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Complete Response Letter (CRL) cited that Phase 3 data did not provide sufficient evidence to support the proposed indication in the U.S. Genentech press release.
- Shingrix (Recombinant Zoster Vaccine, GSK) prefilled syringe presentation was approved for the prevention of shingles (herpes zoster). GSK press release.
- RP1 (vusolimogene oderparepvec, Replimune) was rejected in the treatment of advanced melanoma. The CRL cited trial design and follow-up study issues. Replimune press release.
New data from clinical trials (Phase 2, Phase 3)
Here are the recent updates on Phase 2 and Phase 3 clinical trials with published data between July 15 and 27, 2025:
Viatris reported that the Phase 3 study of pimecrolimus 0.3% (MR-139) ophthalmic ointment in patients with blepharitis did not meet its primary endpoint. Viatris press release.
Alkermes shared positive results from the Phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Alkermes press release.
AstraZeneca announced that the Phase 3 study of anselamimab in patients with Mayo stages IIIa and IIIb light chain (AL) amyloidosis did not meet its primary endpoint. AstraZeneca press release.
Hengrui Pharma and Kailera Therapeutics reported positive data from the Phase 3 trial of HRS9531 in individuals living with obesity or overweight in China. Kailera press release.
Abivax shared positive results from two Phase 3 trials evaluating obefazimod (ABX464) in adult patients with moderately to severely active ulcerative colitis. Abivax press release.
Bristol Myers Squibb announced that its Phase 3 trial of Reblozyl (luspatercept-aamt) in combination with Janus kinase inhibitor (JAKi) therapy in adults with myelofibrosis-associated anemia did not meet its primary endpoint. BMS press release.
SELLAS Life Sciences reported that its Phase 2 trial of SLS009 (tambiciclib) in relapsed/refractory acute myeloid leukemia met all primary endpoints. SELLAS press release.
OKYO Pharma reported positive data from the Phase 2 trial of urcosimod to treat neuropathic corneal pain. OKYO press release.
Apnimed announced that the Phase 3 trial of AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in adults with mild, moderate and severe obstructive sleep apnea met its primary endpoint. Apnimed press release.
